2 not yet recruiting, 2 recruiting, 2 unknown, 1 active not recruiting. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Not yet recruiting 2, Recruiting 2, Unknown 2, Active not recruiting 1, Completed 1, Terminated 1 |
Follow HER2: new trials by email Literature Review of HER2 trials Research Report on HER2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations Almonertinib, Trastuzumab Rezetecan - Lung Cancer (NSCLC), EGFR Activating Mutation | Phase 2 | Not yet recruiting | Yongsheng Wang | 35 | 2026-09-09 | 2026-08-17 |
| MA-CRC-II-016 SHR-1811 SHR-A1811 & Bevacizumab injection, Chemotherapeutic Combinations - mCRC, HER2 | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 80 | 2025-12-30 | 2026-01-21 |
| Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy Trastuzumab+Serplulimab - Urothelial Carcinoma, Biliary Tract Cancer | Phase 2 | Recruiting | Xiujuan Qu | 20 | 2025-07-15 | 2026-04-01 |
| Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment RC48 + Carboplatin - Ovarian Cancer, HER2 | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 20 | 2025-01-04 | 2025-12-16 |
| Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer SOC plus trastuzumab and pembrolizumab - Biliary Tract Cancer, HER2 Gene Mutation | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 24 | 2024-04-17 | 2026-03-27 |
| RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression RC48, Tislelizumab - Non-Muscle Invasive Bladder Cancer, HER2 | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-08-05 | 2023-08-31 |
| Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System chemotherapy in combination with trastuzumab for arm1, chemotherapy in combination with trastuzumab for arm2, chemotherapy in combination with trastuzumab for arm3 - Targeted Therapy, HER2 | Phase 2 | Unknown | Shen Lin | 100 | 2017-07-01 | 2019-07-19 |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Lucitanib - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Terminated | Clovis Oncology, Inc. | 178 | 2014-09-09 | 2020-06-23 |
| PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer PF00299804 - Advanced Gastric Cancer, HER2 | Phase 2 | Completed | Seoul National University Hospital | 28 | 2010-07-01 | 2015-11-20 |
Biliary Tract Neoplasms (3) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Gallbladder Neoplasms (1) · Lung Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Ovarian Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Carcinoma (4) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Biliary Tract Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Breast Diseases (1)
Drug Therapy (2) · Trastuzumab (2) · 26S proteasome non-ATPase regulatory subunit 13 (1) · Bevacizumab (1) · Carboplatin (1) · E-3810 (1) · JPT1 protein, human (1) · RC48 antibody (1) · aumolertinib (1) · dacomitinib (1) · disitamab vedotin (1) · pembrolizumab (1) · tislelizumab (1)
Clovis Oncology, Inc. (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Peking Union Medical College Hospital (1) · RenJi Hospital (1) · Seoul National University Hospital (1) · Shen Lin (1) · Xiujuan Qu (1) · Yongsheng Wang (1) · Zhejiang Cancer Hospital (1)
China (4) · Germany (1) · South Korea (1) · United States (1)
Lin Shen, Master (1) · Salah-Eddin Al-Batran, Prof. Dr. (1) · Yung-Jue Bang, MD, PhD (1)